1
|
Ruiz-de-Adana MS, Domínguez ME, Morillas V, Colomo N, Vallejo-Mora R, Guerrero M, García-Escobar E, Carreira M, Romero-Zerbo Y, Linares F, González-Mariscal I, Bermúdez-Silva FJ, Olveira G, Rojo-Martínez G. Corrigendum to "Efficacy and safety of basal insulin degludec 100 IU/mL versus glargine 300 IU/mL for type 1 diabetes: The single-center INEOX randomized controlled trial" [Diabetes Res. Clin. Pract. 196 (2023) 110238]. Diabetes Res Clin Pract 2024; 210:111620. [PMID: 38514300 DOI: 10.1016/j.diabres.2024.111620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/23/2024]
Affiliation(s)
- María-Soledad Ruiz-de-Adana
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Marta-Elena Domínguez
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain
| | - Virginia Morillas
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain
| | - Natalia Colomo
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain.
| | - Rosario Vallejo-Mora
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain
| | - Mercedes Guerrero
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain
| | - Eva García-Escobar
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Mónica Carreira
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; Department of Personality, Assessment and Psychological Treatment, Faculty of Psychology, University of Málaga, Málaga, Spain
| | - Yanina Romero-Zerbo
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain
| | - Francisca Linares
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Isabel González-Mariscal
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Francisco-Javier Bermúdez-Silva
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Gabriel Olveira
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain; Department of Medicine and Dermatology. University of Málaga, Málaga, Spain
| | - Gemma Rojo-Martínez
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| |
Collapse
|
2
|
Ruiz de Adana MS, Domínguez ME, Morillas V, Colomo N, Vallejo-Mora R, Guerrero M, García-Escobar E, Carreira M, Romero-Zerbo Y, Linares F, González-Mariscal I, Bermúdez-Silva FJ, Olveira G, Rojo-Martínez G. Efficacy and safety of basal insulin degludec 100 IU/mL versus glargine 300 IU/mL for type 1 diabetes: The single-center INEOX randomized controlled trial. Diabetes Res Clin Pract 2023; 196:110238. [PMID: 36610544 DOI: 10.1016/j.diabres.2023.110238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 12/06/2022] [Accepted: 01/03/2023] [Indexed: 01/06/2023]
Abstract
AIMS To compare efficacy and safety of degludec 100 IU/mL (Deg-100) and glargine 300 IU/mL (Gla-300) in adults with type 1 diabetes. METHODS Open-label, single-center, randomized, parallel-group, 24-week trial in adults with type 1 diabetes, on basal-bolus insulin therapy, HbA1c ≤ 10%, using self-monitoring blood glucose. Participants were randomized 1:1 to a basal-bolus insulin regimen with Deg-100 (N = 129) or Gla-300 (N = 131). Primary efficacy endpoint: mean change in HbA1c from baseline to week-24. Main safety outcome: incidence rate of hypoglycemia during the study. Quality of life (DQOL) and satisfaction with diabetes treatment (DTSQ) were assessed. RESULTS At week 24, after adjusting for baseline HbA1c, the decrease in HbA1c did not differ between groups: Deg-100 (-0.07 ± 0.7%) and Gla-300 (-0.16 ± 0.77%) (P = 0.320). There were no significant differences between groups in HbA1c, nocturnal hypoglycemia, severe hypoglycemia, DQOL, or DTSQ scores. The incidence rates of hypoglycemia < 3.9 mmol/L (Deg-100: 115.24 events/person-year vs Gla-300: 99.01 events/person-year, p < 0.001); and < 3.0 mmol/L (Deg-100: 41.17 events/person-year vs Gla-300: 34.29 events/person-year, p < 0.001) were different between groups. CONCLUSIONS Deg-100 and Gla-300 have similar metabolic efficacy, incidence ratio of nocturnal and severe hypoglycemia, DQOL and DTSQ scores. Differences in the incidence rate of hypoglycemia < 3.9 mmol/L and < 3.0 mmol/L should be confirmed.
Collapse
Affiliation(s)
- María Soledad Ruiz de Adana
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Marta Elena Domínguez
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain
| | - Virginia Morillas
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain
| | - Natalia Colomo
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain.
| | - Rosario Vallejo-Mora
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain
| | - Mercedes Guerrero
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain
| | - Eva García-Escobar
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Mónica Carreira
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; Department of Personality, Assessment and Psychological Treatment, Faculty of Psychology, University of Málaga, Málaga, Spain
| | - Yanina Romero-Zerbo
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain
| | - Francisca Linares
- Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Isabel González-Mariscal
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Francisco Javier Bermúdez-Silva
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Gabriel Olveira
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain; Department of Medicine and Dermatology. University of Málaga, Málaga, Spain
| | - Gemma Rojo-Martínez
- Diabetes Unit, Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Plaza del Hospital Civil, 29009 Málaga, Spain; Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| |
Collapse
|
3
|
Leon-Sanz M, Linares F, Gonzalo M, Tapia MJ, Maiz-Jimenez M, Ruiz Aguado M, Lizán L, Olveira G. Compliance with a high-protein and energy-dense oral nutritional supplement in patients with disease-related malnutrition: a randomized open-label crossover trial. Front Nutr 2023; 10:1182445. [PMID: 37200944 PMCID: PMC10186345 DOI: 10.3389/fnut.2023.1182445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Accepted: 04/03/2023] [Indexed: 05/20/2023] Open
Abstract
Introduction Patient compliance with oral nutritional supplements (ONS) is not optimal for meeting energy and nutritional requirements in a high proportion of patients with disease-related malnutrition (DRM). Energy density or prescribed volume of ONS may impact compliance. Methods A randomized, open-label crossover trial was conducted in outpatients with DRM to compare compliance with a high energy-dense ONS (edONS, 2.4 kcal/mL) and a reference ONS (heONS, 2.0 kcal/mL; NCT05609006). Patients were randomly assigned to two 8-week treatment sequences of four-weeks periods: edONS + heONS (sequence A) or heONS + edONS (sequence B). Patients daily reported the amount of product left over gastrointestinal tolerance and satisfaction with ONS. A non-inferiority analysis was performed to compare the compliance rate (percentage of consumed energy over the prescribed) for each period and sequence. Results Fifty-three patients were assigned to sequence A and 50 to sequence B (55.7 ± 13.9 years, 37.0% female, 67.1% oncology patients). In sequence A, the compliance rates were 88.6% ± 14.3% vs. 84.1 ± 21.8% (p = 0.183), while in sequence B, they were 78.9% ± 23.8% vs. 84.4% ± 21.4% (p < 0.01). In both sequences, the lower range of the confidence interval for compliance with edONS was greater than the non-inferiority threshold (for sequence A ΔCompA was 4.5% [95% CI, -2.0% to 10.0%], and for sequence, B ΔCompB was 5.6% [95% CI, -3.0% to 14.0%]). The total discarded cost for each ONS was higher for heONS than edONS, being the difference statistically significant in sequence B. BMI increased slightly and not significantly in both sequences, and the percentage of patients with severe malnutrition was reduced. The frequency of gastrointestinal symptoms was low for both sequences, and satisfaction with ONS was slightly higher for edONS. Conclusion Our findings highlight that edONS was non-inferior to heONS in terms of consumed energy over the prescribed, with a lower amount of edONS discarded, which suggests a higher efficiency of edONS.
Collapse
Affiliation(s)
- Miguel Leon-Sanz
- Department of Endocrinology and Nutrition, Hospital Universitario Doce de Octubre, Madrid, Spain
- Instituto de Investigación 1+12, Madrid, Spain
- Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
- *Correspondence: Miguel Leon-Sanz, ; Gabriel Olveira,
| | - Francisca Linares
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Málaga, Spain
- IBIMA, Instituto de Investigación Biomédica de Málaga y Plataforma BIONAND, Málaga, Spain
- CIBERDEM, Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
| | - Montserrat Gonzalo
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Málaga, Spain
- IBIMA, Instituto de Investigación Biomédica de Málaga y Plataforma BIONAND, Málaga, Spain
| | - María José Tapia
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Málaga, Spain
- IBIMA, Instituto de Investigación Biomédica de Málaga y Plataforma BIONAND, Málaga, Spain
| | - María Maiz-Jimenez
- Department of Endocrinology and Nutrition, Hospital Universitario Doce de Octubre, Madrid, Spain
- Instituto de Investigación 1+12, Madrid, Spain
| | - Marta Ruiz Aguado
- Department of Endocrinology and Nutrition, Hospital Universitario Doce de Octubre, Madrid, Spain
- Instituto de Investigación 1+12, Madrid, Spain
| | - Luis Lizán
- Outcomes’10, Castellón de la Plana, Spain
- Facultad de Medicina, Universidad Jaume I, Castellón de la Plana, Spain
| | - Gabriel Olveira
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Málaga, Spain
- IBIMA, Instituto de Investigación Biomédica de Málaga y Plataforma BIONAND, Málaga, Spain
- CIBERDEM, Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Málaga, Spain
- Facultad de Medicina de Málaga, Universidad de Málaga, Málaga, Spain
- *Correspondence: Miguel Leon-Sanz, ; Gabriel Olveira,
| |
Collapse
|
4
|
Vallejo Mora MDR, Carreira M, Anarte MT, Linares F, Olveira G, González Romero S. Bolus Calculator Reduces Hypoglycemia in the Short Term and Fear of Hypoglycemia in the Long Term in Subjects with Type 1 Diabetes (CBMDI Study). Diabetes Technol Ther 2017; 19:402-409. [PMID: 28594575 PMCID: PMC5563860 DOI: 10.1089/dia.2017.0019] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND In a previous study we demonstrated improvement in metabolic control and reduction in hypoglycemia in people with type 1 diabetes on multiple daily injections, after having used a bolus calculator for 4 months. OBJECTIVE To demonstrate whether (1) extending its use (2) or introducing it in the control group, previously subjected to treatment intensification, could further improve metabolic control and related psychological issues. METHODS After the previous clinical trial, in which the subjects were randomized either to treatment with the calculator or to control group for 4 months, both groups used the calculator during an additional 4-month period. RESULTS In the previous control group, after using the device, HbA1c did not improve (7.86% ± 0.87% vs. 8.01% ± 0.93%, P 0.215), although a significant decrease in postprandial hypoglycemia was observed (2.3 ± 2 vs. 1.1 ± 1.2/2 weeks, P 0.002). In the group in which the treatment was extended from 4 to 8 months, HbA1c did not improve either (7.61 ± 0.58 vs. 7.73 ± 0.65, P 0.209); however this group had a greater perceived treatment satisfaction (12.03 ± 4.26 vs. 13.71 ± 3.75, P 0.007) and a significant decrease in fear of hypoglycemia (28.24 ± 8.18 basal vs. 25.66 ± 8.02 at 8 months, P 0.026). CONCLUSIONS The extension in the use of the calculator or its introduction in a previously intensified control group did not improve metabolic control, although it did confirm a decrease in hypoglycemic episodes in the short term, while the extension of its use to 8 months was associated with a reduction in fear of hypoglycemia and greater treatment satisfaction.
Collapse
Affiliation(s)
- María del Rosario Vallejo Mora
- Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Málaga, Spain
| | - Mónica Carreira
- Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Málaga, Spain
- Personality, Evaluation and Psychological Treatment, School of Psychology, Málaga Spain
| | - María Teresa Anarte
- Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Málaga, Spain
- Personality, Evaluation and Psychological Treatment, School of Psychology, Málaga Spain
| | - Francisca Linares
- Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Málaga, Spain
- CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Barcelona, Spain
| | - Gabriel Olveira
- Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Málaga, Spain
- CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Barcelona, Spain
| | - Stella González Romero
- Endocrinology and Nutrition Department, Hospital Regional Universitario de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Málaga, Spain
- CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Barcelona, Spain
| |
Collapse
|
5
|
Balfegó M, Canivell S, Hanzu FA, Sala-Vila A, Martínez-Medina M, Murillo S, Mur T, Ruano EG, Linares F, Porras N, Valladares S, Fontalba M, Roura E, Novials A, Hernández C, Aranda G, Sisó-Almirall A, Rojo-Martínez G, Simó R, Gomis R. Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial. Lipids Health Dis 2016; 15:78. [PMID: 27090218 PMCID: PMC4836051 DOI: 10.1186/s12944-016-0245-0] [Citation(s) in RCA: 89] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2015] [Accepted: 04/07/2016] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Nutrition therapy is the cornerstone of treating diabetes mellitus. The inclusion of fish (particularly oily fish) at least two times per week is recommended by current international dietary guidelines for type 2 diabetes. In contrast to a large number of human studies examining the effects of oily fish on different cardiovascular risk factors, little research on this topic is available in patients with type 2 diabetes. The aims of this pilot study were to investigate the effects of a sardine-enriched diet on metabolic control, adiponectin, inflammatory markers, erythrocyte membrane fatty acid (EMFA) composition, and gut microbiota in drug-naïve patients with type 2 diabetes. METHODS 35 drug-naïve patients with type 2 diabetes were randomized to follow either a type 2 diabetes standard diet (control group: CG), or a standard diet enriched with 100 g of sardines 5 days a week (sardine group: SG) for 6 months. Anthropometric, dietary information, fasting glycated hemoglobin, glucose, insulin, adiponectin, inflammatory markers, EMFA and specific bacterial strains were determined before and after intervention. RESULTS There were no significant differences in glycemic control between groups at the end of the study. Both groups decreased plasma insulin (SG: -35.3%, P = 0.01, CG: -22.6%, P = 0.02) and homeostasis model of assessment--insulin resistance (HOMA-IR) (SG: -39.2%, P = 0.007, CG: -21.8%, P = 0.04) at 6-months from baseline. However only SG increased adiponectin in plasma compared to baseline level (+40.7%, P = 0.04). The omega-3 index increased 2.6% in the SG compared to 0.6% in the CG (P = 0.001). Both dietary interventions decreased phylum Firmicutes (SG and CG: P = 0.04) and increased E. coli concentrations (SG: P = 0.01, CG: P = 0.03) at the end of the study from baseline, whereas SG decreased Firmicutes/Bacteroidetes ratio (P = 0.04) and increased Bacteroides-Prevotella (P = 0.004) compared to baseline. CONCLUSIONS Although enriching diet with 100 g of sardines 5 days a week during 6 months to a type 2 diabetes standard diet seems to have neutral effects on glycemic control in drug-naïve patients with type 2 diabetes, this nutritional intervention could have beneficial effects on cardiovascular risk. Furthermore, both dietary interventions decreased HOMA-IR and altered gut microbiota composition of drug-naïve patients with type 2 diabetes. TRIAL REGISTRATION Trial number and name of the registry: NCT02294526, ClinicalTrials.gov.
Collapse
Affiliation(s)
- Mariona Balfegó
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain. .,Diabetes and Obesity Research Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), c/ Roselló 149 planta 5, 08036, Barcelona, Spain.
| | - Silvia Canivell
- Diabetes and Obesity Research Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), c/ Roselló 149 planta 5, 08036, Barcelona, Spain.,Les Corts Primary Health Care Center, Tranverse Group for Research in Primary Care, IDIBAPS, c/ Mejia Lequerica s/n, 08028, Barcelona, Spain.,Present address: Centre Hospitalier Universitaire Vaudois (CHUV), Departement de Endocrinologie, Rue Saint-Martin 3, CH-1003, Lausanne, Switzerland
| | - Felicia A Hanzu
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Department of Endocrinology and Nutrition, Hospital Clínic of Barcelona, c/Villarroel 170 Escala 11 planta 2, 08036, Barcelona, Spain.,University of Barcelona, Facultat de Medicina, c/ Casanova 143, 08036, Barcelona, Spain
| | - Aleix Sala-Vila
- CIBER in Physiopathology of Obesity and Nutrition (CIBERobn), c/Villarroel 170, Edifici Helios, 08036, Barcelona, Spain
| | - Margarita Martínez-Medina
- Laboratory of Molecular Microbiology, Biology Department, University of Girona, Av. Montilivi s/n, E-17071, Girona, Spain
| | - Serafín Murillo
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Diabetes and Obesity Research Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), c/ Roselló 149 planta 5, 08036, Barcelona, Spain
| | - Teresa Mur
- Terrassa Sud Primary Health Care Center, Mútua de Terrassa, Av. Santa Eulàlia s/n, 08223, Terrassa, Barcelona, Spain
| | - Elena G Ruano
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Diabetes and Obesity Research Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), c/ Roselló 149 planta 5, 08036, Barcelona, Spain
| | - Francisca Linares
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Endocrinology and Nutrition Department, Hospital Carlos Haya, Biomedical Research Institute of Málaga (IBIMA), Plaza Hospital Civil s/n Sótano Pabellón 1, 29009, Málaga, Spain
| | - Nuria Porras
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Endocrinology and Nutrition Department, Hospital Carlos Haya, Biomedical Research Institute of Málaga (IBIMA), Plaza Hospital Civil s/n Sótano Pabellón 1, 29009, Málaga, Spain
| | - Silvia Valladares
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Vall d'Hebrón Research Institute and Autonomous University of Barcelona, Pg. de la Vall d'Hebrón 119-129 planta 8, Barcelona, Spain
| | - Maria Fontalba
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Endocrinology and Nutrition Department, Hospital Carlos Haya, Biomedical Research Institute of Málaga (IBIMA), Plaza Hospital Civil s/n Sótano Pabellón 1, 29009, Málaga, Spain
| | - Elena Roura
- Alicia Foundation, Camí Sant Benet, 08272 Sant Fruitós de Bages, Barcelona, Spain
| | - Anna Novials
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Diabetes and Obesity Research Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), c/ Roselló 149 planta 5, 08036, Barcelona, Spain.,Department of Endocrinology and Nutrition, Hospital Clínic of Barcelona, c/Villarroel 170 Escala 11 planta 2, 08036, Barcelona, Spain
| | - Cristina Hernández
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Vall d'Hebrón Research Institute and Autonomous University of Barcelona, Pg. de la Vall d'Hebrón 119-129 planta 8, Barcelona, Spain
| | - Gloria Aranda
- Department of Endocrinology and Nutrition, Hospital Clínic of Barcelona, c/Villarroel 170 Escala 11 planta 2, 08036, Barcelona, Spain
| | - Antoni Sisó-Almirall
- Les Corts Primary Health Care Center, Tranverse Group for Research in Primary Care, IDIBAPS, c/ Mejia Lequerica s/n, 08028, Barcelona, Spain.,University of Barcelona, Facultat de Medicina, c/ Casanova 143, 08036, Barcelona, Spain
| | - Gemma Rojo-Martínez
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Endocrinology and Nutrition Department, Hospital Carlos Haya, Biomedical Research Institute of Málaga (IBIMA), Plaza Hospital Civil s/n Sótano Pabellón 1, 29009, Málaga, Spain
| | - Rafael Simó
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Vall d'Hebrón Research Institute and Autonomous University of Barcelona, Pg. de la Vall d'Hebrón 119-129 planta 8, Barcelona, Spain
| | - Ramon Gomis
- CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), c/ Monforte de Lemos 3-5 Pabellón 11 planta 0, 28029, Madrid, Spain.,Diabetes and Obesity Research Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), c/ Roselló 149 planta 5, 08036, Barcelona, Spain.,Department of Endocrinology and Nutrition, Hospital Clínic of Barcelona, c/Villarroel 170 Escala 11 planta 2, 08036, Barcelona, Spain.,University of Barcelona, Facultat de Medicina, c/ Casanova 143, 08036, Barcelona, Spain
| |
Collapse
|
6
|
Ruiz de Adana MS, Colomo N, Maldonado-Araque C, Fontalba MI, Linares F, García-Torres F, Fernández R, Bautista C, Olveira G, de la Cruz JL, Rojo-Martínez G, Valdés S. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease. Diabetes Res Clin Pract 2015; 110:158-65. [PMID: 26474657 DOI: 10.1016/j.diabres.2015.09.015] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2015] [Revised: 09/05/2015] [Accepted: 09/12/2015] [Indexed: 01/08/2023]
Abstract
AIMS To investigate the clinical efficacy and safety of insulin glargine compared with NPH insulin as basal insulin for the management of corticosteroid-induced hyperglycemia in hospitalized people with type 2 diabetes (T2DM) and respiratory disease. MATERIALS AND METHODS Randomized, two-arm parallel group, clinical trial undertaken from February 2011 to November 2012 on the pneumology ward of the Hospital Regional Universitario de Málaga (Spain), involving 53 participants with T2DM treated with medium/high doses of intermediate-acting corticosteroids. Participants were randomly assigned to receive one single dose of insulin glargine or NPH insulin in three equally divided doses before each meal as basal insulin within a basal-bolus insulin protocol. The intervention lasted six days or until discharge if earlier. RESULTS No significant differences were seen between groups during the study in mean blood glucose (11.43±3.44 mmol/l in glargine vs. 11.88±2.94 mmol/l in NPH, p=0.624), and measures of glucose variability (standard deviation 3.27±1.16 mmol/l vs. 3.61±0.99 mmol/l, p=0.273; coefficient of variation 1.55±0.33 mmol/l vs. 1.72±0.39 mmol/l, p=0.200). Results from CGM were concordant with those obtained with capillary blood glucose reading. The length of hospital stay was also similar between groups (8.2±2.8 days vs. 9.8±3.4 days, p=0.166) There was a non significant trend for lower episodes of mild (4 vs. 8, p=0.351) and severe hypoglycemia (0 vs. 3, p=0.13) in the glargine group. CONCLUSIONS The results of this study showed that insulin glargine and NPH insulin are equally effective in a basal-bolus insulin protocol to treat glucocorticoid-induced hyperglycemia in people with T2DM on a pneumology ward.
Collapse
Affiliation(s)
- María S Ruiz de Adana
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain.
| | - Natalia Colomo
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain
| | - Cristina Maldonado-Araque
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain
| | - María I Fontalba
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain
| | - Francisca Linares
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain
| | - Francisca García-Torres
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain
| | - Rosario Fernández
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain
| | - Carmen Bautista
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain
| | - Gabriel Olveira
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain
| | - José L de la Cruz
- Department of Pneumology, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain
| | - Gemma Rojo-Martínez
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain
| | - Sergio Valdés
- Department of Endocrinology and Nutrition, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain
| |
Collapse
|
7
|
Esmatjes E, Jansà M, Roca D, Pérez-Ferre N, del Valle L, Martínez-Hervás S, Ruiz de Adana M, Linares F, Batanero R, Vázquez F, Gomis R, de Solà-Morales O. The efficiency of telemedicine to optimize metabolic control in patients with type 1 diabetes mellitus: Telemed study. Diabetes Technol Ther 2014; 16:435-41. [PMID: 24528195 DOI: 10.1089/dia.2013.0313] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
OBJECTIVE This study evaluated the impact of an Internet-based telematic system on the economic and clinical management of patients with type 1 diabetes mellitus. RESEARCH DESIGN AND METHODS This 6-month prospective, randomized, comparative, open, multicenter study included patients with type 1 diabetes >18 years old treated with multiple insulin doses and with a glycated hemoglobin (HbA1c) level of >8%. We compared an intervention group (IG) (two face-to-face and five telematic appointments) with a control group (CG) (seven face-to-face appointments). The variables studied were (1) patient and healthcare team costs, (2) metabolic control, (3) knowledge of diabetes, (4) quality of life, and (5) self-care treatment adherence. RESULTS Of the 154 patients included, 118 (76.6%) completed the study (IG, 54; CG, 64). The time used by the CG to follow the program was 823±645 min versus 353±222 min in the IG (P<0.0001). Compared with the CG, the IG required less healthcare time from the professionals (288±105 min vs. 232±89 min; P<0.001). HbA1c improved in both groups (IG, 9.2±1.5% [77.0±17.0 mmol/mol] vs. 8.7±1.5% [71.6±17.0 mmol/mol] [P<0.001]; CG, 9.2±0.9% [77.0±10.0 mmol/mol] vs. 8.6±0.9% [70.5±10.0 mmol/mol] [P<0.001], as did knowledge and self-care treatment adherence. CONCLUSIONS The use of interactive telematic appointments in subjects with type 1 diabetes and inadequate metabolic control is an efficient strategy, providing results comparable to those of face-to-face appointments in relation to improvement in glycemic control, knowledge acquisition, and self-care treatment adherence, with a significant reduction in the time used, especially by patients.
Collapse
Affiliation(s)
- Enric Esmatjes
- 1 Diabetes Unit, Hospital Clinic, University of Barcelona , Biomedical Research Center in Diabetes and Associated Metabolic Disorders, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Gutiérrez-Repiso C, Velasco I, Garcia-Escobar E, Garcia-Serrano S, Rodríguez-Pacheco F, Linares F, Ruiz de Adana MS, Rubio-Martin E, Garrido-Sanchez L, Cobos-Bravo JF, Priego-Puga T, Rojo-Martinez G, Soriguer F, García-Fuentes E. Does dietary iodine regulate oxidative stress and adiponectin levels in human breast milk? Antioxid Redox Signal 2014; 20:847-53. [PMID: 24001137 PMCID: PMC3910559 DOI: 10.1089/ars.2013.5554] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Little is known about the association between iodine and human milk composition. In this study, we investigated the association between iodine and different markers of oxidative stress and obesity-related hormones in human breast milk. This work is composed of two cross-sectional studies (in lactating women and in the general population), one prospective and one in vitro. In the cross-sectional study in lactating women, the breast milk iodine correlated negatively with superoxide dismutase (SOD), catalase, and glutathione peroxidase (GSH-Px) activities, and with adiponectin levels. An in vitro culture of human adipocytes with 1 μM potassium iodide (KI, dose similar to the human breast milk iodine concentration) produced a significant decrease in adiponectin, GSH-Px, SOD1, and SOD2 mRNA expression. However, after 2 months of treatment with KI in the prospective study, a positive correlation was found between 24-h urinary iodine and serum adiponectin. Our observations lead to the hypothesis that iodine may be a factor directly involved in the regulation of oxidative stress and adiponectin levels in human breast milk.
Collapse
Affiliation(s)
- Carolina Gutiérrez-Repiso
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Málaga, Spain
| | - Inés Velasco
- Unidad de Gestión Clínica Materno-Infantil, Hospital de Riotinto, Huelva, Spain
| | - Eva Garcia-Escobar
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Málaga, Spain
| | - Sara Garcia-Serrano
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Málaga, Spain
| | - Francisca Rodríguez-Pacheco
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Málaga, Spain
| | - Francisca Linares
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Málaga, Spain
| | - Maria Soledad Ruiz de Adana
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Málaga, Spain
| | - Elehazara Rubio-Martin
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Málaga, Spain
| | - Lourdes Garrido-Sanchez
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
- CIBER Fisiología de la Obesidad y Nutrición (CIBEROBN), Málaga, Spain
| | - Juan Francisco Cobos-Bravo
- Unidad de Gestión Clínica de Cirugia General, Digestiva y Transplantes, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
| | - Tatiana Priego-Puga
- Unidad de Gestión Clínica de Cirugia General, Digestiva y Transplantes, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
| | - Gemma Rojo-Martinez
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Málaga, Spain
| | - Federico Soriguer
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
- CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), Málaga, Spain
- CIBER Fisiología de la Obesidad y Nutrición (CIBEROBN), Málaga, Spain
| | - Eduardo García-Fuentes
- Unidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Regional Universitario Carlos Haya, Málaga, Spain
- CIBER Fisiología de la Obesidad y Nutrición (CIBEROBN), Málaga, Spain
| |
Collapse
|
9
|
|
10
|
Colomo N, Linares F, Rubio-Martín E, Moreno MJ, de Mora M, García AM, González AM, Rojo-Martínez G, Valdés S, Ruiz de Adana MS, Olveira G, Soriguer F. Stress hyperglycaemia in hospitalized patients with coronary artery disease and type 2 diabetes risk. Eur J Clin Invest 2013; 43:1060-8. [PMID: 23980841 DOI: 10.1111/eci.12144] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2013] [Accepted: 07/24/2013] [Indexed: 01/08/2023]
Abstract
AIMS (i) To evaluate glucometabolic status of patients without known diabetes hospitalized due to coronary artery disease (CAD), (ii) to assess markers of systemic inflammation determined during admission and to evaluate their relationship with glucometabolic status and (iii) to analyse usefulness of HbA1c determined during admission in patients with CAD to detect abnormal glucose regulation (AGR). MATERIALS & METHODS We studied 440 patients with CAD admitted to the cardiology ward. Patients were grouped in four groups during admission according to clinical data, fasting plasma glucose and HbA1c: diabetes, HbA1c > 5·9%, stress hyperglycaemia (SH) and normal. In 199 subjects without known diabetes, an oral glucose tolerance test (OGTT) was performed 3 months after discharge, and they were reclassified according to WHO 1998 criteria. Biochemical and inflammatory markers were measured. RESULTS The OGTT showed that 27·4% of subjects without known diabetes at admission had diabetes, 11·2% had impaired fasting glucose + impaired glucose tolerance, 33·5% impaired glucose tolerance, 3·6% impaired fasting glucose, and 24·4% normal glucose metabolism. Odds ratio for having diabetes 3 months after discharge in HbA1c > 5·9% group was 5·91 (P < 0·0001) and in SH group was 1·82 (P = 0·38). The best HbA1c cut-off point to predict AGR was 5·85%. HbA1c levels during admission were highly predictive of having AGR (AUC ROC 0·76 [95% CI 0·67-0·84]). CONCLUSION We reported a high prevalence of AGR in subjects with CAD. Stress hyperglycaemia in patients with CAD was not associated with an increased risk of diabetes 3 months later. HbA1c in patients hospitalized with CAD was a useful tool to detect AGR.
Collapse
Affiliation(s)
- Natalia Colomo
- Endocrinology and Nutrition Department, Hospital Universitario Carlos Haya, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Málaga, Spain; CIBERDEM (CB07/08/0019) of the Instituto de Salud Carlos III, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
González-Molero I, Domínguez-López M, Guerrero M, Carreira M, Caballero F, Rubio-Martín E, Linares F, Cardona I, Anarte MT, de Adana MSR, Soriguer F. Use of telemedicine in subjects with type 1 diabetes equipped with an insulin pump and real-time continuous glucose monitoring. J Telemed Telecare 2012; 18:328-32. [PMID: 22912487 DOI: 10.1258/jtt.2012.120103] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
We evaluated a telemedicine system in patients with type 1 diabetes who had optimized treatment with an insulin pump and a real-time continuous glucose monitoring system. We conducted a prospective, one-year study of 15 subjects. Three medical visits took place: pre-baseline, baseline and at 6 months. Each month the subjects transmitted information from the glucose meter, glucose sensor and insulin pump. We adjusted the treatment and returned the information by email. We evaluated psychological and metabolic variables, including HbA(1c), hypoglycaemia, hyperglycaemia and glucose variability. At baseline the mean age of the subjects was 40 years and the mean duration of diabetes was 22 years. There was a significant reduction in HbA(1c) (7.50 to 6.97%) at 6 months, a significant increase in the number of self-monitoring blood glucose checks per day (5.2 to 6.2), and significant improvements in variability: MODD, mean of daily difference (67 to 53) and MAGE, mean amplitude of glycaemic excursions (136 to 102). There were significant improvements in quality of life (92 to 87), satisfaction with the treatment (34 to 32) and less fear of hypoglycaemia (36 to 32). Adult subjects with type 1 diabetes on treatment with a continuous insulin infusion system and a real time glucose sensor and who have acceptable metabolic control and optimized treatment can benefit from the addition of a telemetry system to their usual outpatient follow-up.
Collapse
Affiliation(s)
- Inmaculada González-Molero
- Servicio de Endocrinología y Nutrición, Hospital Regional Universitario Carlos Haya, sótano P1., Avda del Dr. Gálvez Ginachero s/n, 29009 Málaga, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Ghitis J, Velez H, Linares F, Sinisterra L, Vitale JJ. Cali-Harvard nutrition project. II. The erythroid atrophy of kwashiorkor and marasmus. Am J Clin Nutr 1998; 12:445-51. [PMID: 13947506 DOI: 10.1093/ajcn/12.6.445] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Medina I, Linares F, Garrido J. Use of a packed programmed-temperature vaporizer injector in the solvent elimination mode for the determination of fatty acid methyl esters by gas chromatography. J Chromatogr A 1994. [DOI: 10.1016/0021-9673(94)85089-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Salvador F, Linares F, Merita I, Amen M. Unilateral iridoschisis associated with syphilitic interstitial keratitis and glaucoma. Ann Ophthalmol 1993; 25:328-9. [PMID: 8297067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Iridoschisis is a rare condition that consists of the separation of the anterior mesodermic layer of the iris. It is associated with glaucoma in 50% of cases. The association of this disorder with luetic interstitial keratitis has been reported rarely. We report the case of a 58-year-old patient who had unilateral iridoschisis associated with glaucoma and syphilitic interstitial keratitis. We suggest that congenital syphilis might be considered as a cause of iridoschisis.
Collapse
Affiliation(s)
- F Salvador
- Section of Ophthalmology, Hospital Universitario Vall D'Hebron, Barcelona, Spain
| | | | | | | |
Collapse
|
15
|
Montoro JB, Lalueza P, Cano SM, Escobar C, Linares F. Drop size and systemic adverse effects in timolol ophthalmic solution. DICP 1990; 24:439-40. [PMID: 2327120 DOI: 10.1177/106002809002400421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- J B Montoro
- Hospital Pharmacy Service, Hospital General Vall d'Hebron, Barcelona, Spain
| | | | | | | | | |
Collapse
|
16
|
Molins A, Alvarez-Sabin J, Linares F, Montalbán J. [Neuroretinitis as a presenting form of secondary syphilis]. Med Clin (Barc) 1987; 89:215. [PMID: 3626681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
17
|
Pujol A, Linares F, Muñoz J, Rusconi A, Orejas V, Serrallach N, Acomar P. A new method for detection and localization of urinary infection. The fluorescence antibody test. Urol Int 1976; 31:501-7. [PMID: 827041 DOI: 10.1159/000280085] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The urinary sediment of 56 patients with active urinary infection were studied through a direct immunofluorescence technique in order to detect the presence of antibody-coated bacteria. In 35-36 pyelonephritis cases the results were positive. However, in 11 cases with lower urinary infection there was no sign of antibody coasted bacteria. A pathological intravenous pyelogram (IVP) was obtained from 33 pyelonephritic cases. In the flurorescent antibody (FA) test was positive, one was negative. In the remaining three pyelonephritic cases the IVP was normal the the FA test positive. In these three cases, cystography revealed the presence of ureterovesical backflow. A good statistical correlation was obtained by comparing the positive results of the test with the titer of serum antibody against the bacteria causing the infection. We have introduced some variation to the original method which permits simpler administration of this test to ambulatory patients and increases the diagnostic possibility of those cases of bacteriuria less than 100,000 bacteria/ml.
Collapse
|
18
|
Pujol A, Linares F, Muñoz J, Rusconi A, Orejas V, Serrallach N, Acomar P. A new method for detection and localization of urinary infection: the fluorescence antibody test. Eur Urol 1976; 2:145-8. [PMID: 800990 DOI: 10.1159/000471986] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The urinary sediment of 56 patients with active urinary infection were studied through a direct immunofluorescence technique in order to detect the presence of antibody-coated bacteria (ACB). In 35-36 pyelonephritis cases the results were positive. However, in 11 cases with lower urinary infection there was no sign of ACB. A pathological intravenous pyelogram (IVP) was obtained from 33 pyelonephritic cases. In 32 cases the fluorescent antibody (FA) test was positive, in one it was negative. In the remaining 3 pyelonephritic cases the IVP was normal and the FA test positive. In these 3 cases cystograph revealed presence of urethral-vesical backflow. A good statistical correlation was obtained by comparing the positive results of the test with the titer of sericeous antibody against the bacteria causing the infection. We have introduced some variations to the original method which permits simpler administration of this test to ambulatory patients and increases the diagnostic possibility of those cases of bacteriuria less than 100,000 bacteria/ml.
Collapse
|
19
|
Maner JH, Pond WG, Gallo JT, Henao A, Portela R, Linares F. Performance of rats and swine fed Colombian floury-2, Colombian opaque-2 or normal corn. J Anim Sci 1971; 33:791-6. [PMID: 5092774 DOI: 10.2527/jas1971.334791x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|